{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T19:41:49Z","timestamp":1769197309383,"version":"3.49.0"},"reference-count":8,"publisher":"Japanese Society of Internal Medicine","issue":"19","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2020,10,1]]},"DOI":"10.2169\/internalmedicine.4824-20","type":"journal-article","created":{"date-parts":[[2020,6,29]],"date-time":"2020-06-29T22:06:20Z","timestamp":1593468380000},"page":"2419-2421","source":"Crossref","is-referenced-by-count":4,"title":["Dasatinib-induced Reversible Demyelinating Peripheral Neuropathy and Successful Conversion to Nilotinib in Chronic Myelogenous Leukemia"],"prefix":"10.2169","volume":"59","author":[{"given":"Hiroyasu","family":"Inoue","sequence":"first","affiliation":[{"name":"Department of Neurology, Nagoya City East Medical Center, Japan"},{"name":"Department of Neurology and Neuroscience, Nagoya City University Graduate School of Medical Sciences, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hirofumi","family":"Taji","sequence":"additional","affiliation":[{"name":"Department of Hematology and Cell Therapy, Aichi Cancer Center Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kentaro","family":"Yamada","sequence":"additional","affiliation":[{"name":"Department of Neurology, Nagoya City East Medical Center, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chisako","family":"Iriyama","sequence":"additional","affiliation":[{"name":"Department of Hematology and Cell Therapy, Aichi Cancer Center Hospital, Japan"},{"name":"Department of Hematology and Oncology, Fujita Health University, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Touko","family":"Saito","sequence":"additional","affiliation":[{"name":"Department of Hematology and Cell Therapy, Aichi Cancer Center Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Harumi","family":"Kato","sequence":"additional","affiliation":[{"name":"Department of Hematology and Cell Therapy, Aichi Cancer Center Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masamitsu","family":"Yanada","sequence":"additional","affiliation":[{"name":"Department of Hematology and Cell Therapy, Aichi Cancer Center Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuhito","family":"Yamamoto","sequence":"additional","affiliation":[{"name":"Department of Hematology and Cell Therapy, Aichi Cancer Center Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noriyuki","family":"Matsukawa","sequence":"additional","affiliation":[{"name":"Department of Neurology and Neuroscience, Nagoya City University Graduate School of Medical Sciences, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"962","reference":[{"key":"1","unstructured":"1. Kennedy JA, Hobbs G. Tyrosine kinase inhibitors in the treatment of chronic-phase CML: strategies for frontline decision-making. Curr Hematol Malig Rep 13: 202-211, 2018."},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Ishida T, Akagawa N, Miyata T. Dasatinib-associated reversible demyelinating peripheral polyneuropathy in a case of chronic myeloid leukemia. Int J Hematol 107: 373-377, 2018.","DOI":"10.1007\/s12185-017-2339-5"},{"key":"3","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/s40959-015-0008-5","volume":"1","author":"O Pasvolsky","year":"2015","unstructured":"3. Pasvolsky O, Leader A, Iakobishvili Z, et al. Tyrosine kinase inhibitor associated vascular toxicity in chronic myeloid leukemia. Cardio-Oncology 1: 5, 2015.","journal-title":"Cardio-Oncology","ISSN":"https:\/\/id.crossref.org\/issn\/2057-3804","issn-type":"print"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Melfi S, Montt Guevara MM, Bonalume V, et al. Src and phospho-FAK kinases are activated by allopregnanolone promoting Schwann cell motility, morphology and myelination. J Neurochem 141: 165-178, 2017.","DOI":"10.1111\/jnc.13951"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Fraser CK, Lousberg EL, Kumar R, et al. Dasatinib inhibits the secretion of TNF-alpha following TLR stimulation <i>in vitro<\/i> and <i>in vivo<\/i>. Exp Hematol 37: 1435-1444, 2009.","DOI":"10.1016\/j.exphem.2009.09.007"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. RP Lisak. Cytokines and chemokines in inflammatory demyelinating neuropathies. Clin Exp Neuroimmunol 1: 153-164, 2010.","DOI":"10.1111\/j.1759-1961.2010.00015.x"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. St\u00fcbgen JP. Tumor necrosis factor-alpha antagonists and neuropathy. Muscle Nerve 37: 281-292, 2008.","DOI":"10.1002\/mus.20924"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Judge C, Moheb N, Melinosky C. Nilotinib-associated demyelinating disease. Neurology 92 (Suppl): P2.2-093, 2019.","DOI":"10.1212\/WNL.92.15_supplement.P2.2-093"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/59\/19\/59_4824-20\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,8]],"date-time":"2024-08-08T19:23:44Z","timestamp":1723145024000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/59\/19\/59_4824-20\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,1]]},"references-count":8,"journal-issue":{"issue":"19","published-print":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.4824-20","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,10,1]]}}}